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Background: Vitamin A supplementation (VAS) may amplify the effect of vaccines. We therefore investigated if
neonatal VAS given with and without Bacille Calmette-Guérin (BCG) vaccine to low-birth-weight (LBW) neonates
had an effect on growth in the first year of life. We hypothesised that VAS would be particularly beneficial when
provided with BCG.
Methods: We conducted a randomised two-by-two factorial trial in Guinea-Bissau; 1,717 LBW neonates were
randomly allocated to VAS or placebo at birth as well as early or the usual postponed BCG vaccination.
Anthropometric measurements were obtained at 2, 6, and 12 months after inclusion.
Results: Overall there was no effect of neonatal VAS on growth in the first year of life. By 2 months, VAS tended to
have a beneficial effect on weight and head circumference when given with BCG but not when given without BCG
(interaction: weight-for-age p = 0.07 and head circumference-for-age: p = 0.06). By 6 months, there was a beneficial
effect of VAS on head circumference and weight among children who had not received DTP vaccine 2 months
after inclusion (weight: 0.18 (0.00; 0.36) and head circumference 0.27 (0.06; 0.48)), but no beneficial effect among
those who had received DTP.
Conclusion: The results support other trials indicating that neonatal VAS does not have consistent effects on
childhood growth and if anything the effects seem to be temporary. They also show that the effect may differ by
vaccination status, being beneficial when given with BCG at birth and when DTP is delayed.
Trial registration: www.ClinicalTrials.gov (NCT00168610).
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Observational studies have shown that low dietary vitamin
A intake and vitamin A deficiency are associated with
impaired childhood growth [1-3]. However, a meta-analysis
concluded that there was no overall effect of vitamin
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distribution, and reproduction in any medium48 months of age on subsequent growth [4] though it
should be noted that one study found that the effect of
VAS on growth may differ according to the children’s
vitamin A status at the time of supplementation [5]. Only
two studies have examined the effect on growth of a single
dose of VAS at birth. An Indonesian study including only
children with a birth weight ≥ 1500 g found an increase in
length at 3 years of age among VAS recipients [6].
Another study conducted in Guinea-Bissau among
normal-birth-weight infants (NBW; ≥ 2,500 g) found
a positive effect on weight-for-length as long as
Bacille Calmette-Guérin (BCG) vaccine was the mostd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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a negative effect among children who had received
diphtheria-tetanus-pertussis (DTP) vaccine [7]. None of
the trials included children with very low birth weight,
who are known to have poorer vitamin A status [8,9].
We have previously hypothesised that VAS amplifies
the non-specific effects of routine vaccinations [10,11].
The non-specific effects are the effects of vaccines that
cannot be ascribed to the protection against the targeted
disease. More specifically, we hypothesised that VAS may
amplify the beneficial non-specific effects of the BCG
vaccine [10,11]. To test this hypothesis we conducted a
trial among low birth weight neonates (LBW; <2,500 g),
who normally do not receive BCG vaccine at birth, but
only when they have gained weight. In a two-by-two
factorial design, LBW neonates were randomly allocated
to 25,000 IU vitamin A or placebo and to early BCG or
the usual delayed BCG vaccination. When studying the
effects on mortality, we found no interactions between
BCG and VAS [12,13]. We found no effect of neonatal
VAS on infant mortality, but a significant sex-differential
effect with a tendency for a beneficial effect in males,
but a tendency for a negative effect in females [12].
In the present paper, we have examined the effect on
growth of neonatal VAS among LBW children and
whether the effect differed by vaccination status
(BCG and DTP).
Methods
Setting
The Bandim Health Project (BHP) runs a health and
demographic surveillance system in the capital of
Guinea-Bissau. The present growth study was a part
of a two-by-two factorial trial on VAS and BCG at
birth which has been described elsewhere [12,13]. In
brief, LBW children born at the national hospital
from May 2005 to January 2008 were invited to partici-
pate. The study was explained to the mothers/guardians
in the local language and they received a written
explanation in Portuguese. If the mothers/guardians
wished to participate, they were asked to sign or put
a fingerprint on a consent form. Provided consent,
the children were randomly assigned to vitamin A or
placebo and to early BCG or the usual postponed
BCG. Children assigned to “early BCG” were vaccinated
intradermally with 0.05 ml BCG vaccine (Statens Serum
Institut, Copenhagen, Denmark). The children who
were not assigned to BCG were treated according to
local practice and hence not vaccinated at birth. The
vitamin A supplement contained 0.5 ml oil with
25,000 IU vitamin A and 10 IU vitamin E; placebo
was 0.5 ml oil with 10 IU vitamin E (Skanderborg
Apotek, Denmark). The VAS/placebo part of the
study was blinded.Anthropometrics
Weight, length as well as arm and head circumference
were measured by trained field assistants at enrolment
and at home visits 2, 6, and 12 months after enrolment.
Weight of the undressed child was measured using an
electronic scale (SECA Model 835). Length was measured
with a measuring mat (SECA Model 210) while the child
was lying down. A non-stretching measuring tape (SECA
Model 212) was used to measure head circumference. The
mid upper arm circumference (MUAC) was measured on
the left arm with a non-stretch TALC tape.
If a child was temporarily absent, the assistants would
revisit the child one of the following days. Travelling
children were revisited at the next round of visits. Children
who had moved within Bissau city were located with
the help from neighbours. At all follow up visits vaccine
information was collected. Most children are breastfed up
to 2 years of age [14]; in the present cohort 98% were
breastfed by 2 months of age [15].
Statistical analysis
Measures for weight, length and head circumference
were converted to z-scores using the 2006 WHO
reference standards [16]. Children were classified as
underweight and stunted if they had a weight-for-age
z-score < −2 and a length-for-age z-score < −2, respect-
ively. We did not convert MUAC to z-scores since it
is not possible to calculate MUAC z-scores for
children below 3 months of age and furthermore, we
have found that crude MUAC is as good an indicator
of mortality risk as MUAC z-score [17]. The effect of
VAS on growth was analysed at 2, 6, and, 12 months
after enrolment. We used linear regression to com-
pare z-scores at the different time points and calcu-
lated relative risks of being stunted or underweight in
Poisson regression models with robust standard errors
[18]. We adjusted all analyses for the corresponding
anthropometric parameter measured at inclusion. As
this was a two-by-two factorial trial, all analyses
where done for the entire cohort controlled for
randomisation to BCG as well as separately in the BCG
and No BCG groups. The analyses were also stratified by
sex since neonatal VAS might have sex-differential
effects [12,19,20].
To study the effect of receiving early or late DTP, we
divided the children into two groups; children who had
received a DTP vaccine before or on the day of the
2 months visit (Early DTP group) and children who
received a DTP vaccine after the day of the 2 months visit
(Delayed DTP group) [15] We analysed the effect of
VAS on weight-for-age, length-for-age, and head
circumference-for-age at 6 months of age adjusted for the
corresponding measurement at 2 months of age and for
randomisation to BCG in the two DTP groups.
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enrolment but as weight is an indicator of vitamin A status
[8,9], we examined whether weight group at inclusion
modified the effect of VAS on growth.
Ethical approval
The protocol was approved by the Danish Central
Ethics Committee and the Guinean Ministry of Health’s
Research Coordination Committee.
Results
A total of 1,717 children were randomised to VAS or
placebo. At baseline the VAS and placebo groups were
comparable [12]. Only 203 children were never measured
for growth. The majority had died (n = 93) or were
travelling at the time of the visit (n = 72) (Figure 1).
These children showed the same distribution of back-
ground factors between the VAS and placebo groups
(Additional file 1).
Overall there was no difference in weight, length and
head circumference between the VAS and placebo
groups 2 months after enrolment adjusted for baseline
anthropometric measurements and randomisation to BCGRandom
n=1,73
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Figure 1 Flow of children through the study.(Table 1). The effect of VAS on head circumference-
for-age tended to differ with whether given with or
without BCG (interaction p = 0.06); the effect of VAS
was beneficial when given with BCG (0.16 (0.00; 0.32)),
but not when VAS was given without BCG (−0.06 (−0.22;
0.10)). This tendency may have been strongest among
boys in whom the beneficial effect of VAS given with BCG
was significant (head circumference: 0.37 (0.06; 0.69); head
circumference-for-age: 0.26 (0.01; 0.49)). For weight there
also was the same tendency towards a beneficial effect of
VAS when given with BCG and a negative effect
when given without BCG (Interaction: weight p = 0.08;
weight-for-age p = 0.07), Neonatal VAS had no effect
on MUAC at 2 months after enrolment and no effect on
any of the anthropometric parameters at 6 and 12 months
after enrolment, neither overall nor separately in the early
BCG and No BCG groups (Additional file 2).
Stratified by the children’s DTP status at the
2 months visit, the effect of VAS on weight-for-age
and head circumference-for-age was beneficial at
6 months after enrolment if the child had not
received a DTP vaccine at 2 months (weight: 0.18
(0.00; 0.36), head circumference: 0.27 (0.06; 0.48))ised 
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Table 1 Neonatal vitamin A supplementation (VAS) and anthropometric measurements at 2 months, overall and by BCG-group
Overall BCG No BCG Interaction between
BCG and VAS
All VAS Placebo Difference*
(CI: 95%)
RR *
(CI: 95%)
VAS Placebo Difference**
(CI: 95%)
RR **
(CI: 95%)
VAS Placebo Difference**
(CI: 95%)
RR **
(CI: 95%)
Number 693 697 353 350 340 347
Median age in days 67 66 67 66 66 66
Weight, kg 4.25 4.29 −0.01
(−0.07; 0.06)
4.27 4.24 0.05
(−0.04; 0.14)
4.22 4.34 −0.07
(−0.16; 0.03)
P = 0.08
Weight-for-age
(WAZ), z-score
−2.13 −2.08 −0.02
(−0.12; 0.09)
−2.09 −2.19 0.08
(−0.07; 0.23)
−2.17 −1.98 −0.11
(−0.26; 0.04)
P = 0.07
Underweight
(WAZ < −2)
35% 36% 0.95
(0.83; 1.07)
35% 37% 0.90
(0.76; 1.08)
35% 35% 0.99
(0.83; 1.19)
P = 0.48
Length, cm 53.0 53.3 −0.11
(−0.37; 0.13)
52.9 53.2 −0.10
(−0.45; 0.25)
53.1 53.4 −0.13
(−0.49; 0.22)
P = 0.88
Length-for-age
(LAZ), z-score
−2.67 −2.53 −0.06
(−0.17; 0.05)
−2.71 −2.58 −0.04
(−0.20; 0.12)
−2.62 −2.48 −0.09
(−0.24; 0.07)
P = 0.66
Stunting (LAZ <−2) 51% 48% 1.05
(0.93; 1.11)
51% 49% 1.07
(0.94; 1.22)
51% 46% 1.02
(0.90; 1.16)
P = 0.61
Head circumference,
cm
37.4 37.4 0.05
(−0.10; 0.21)
37.5 37.4 0.18
(−0.04; 0.40)
37.3 37.5 −0.08
(−0.30; 0.14)
P = 0.10
Head circumference-
for-age, z-score
−1.32 −1.34 0.05
(−0.06; 0.17)
−1.25 −1.39 0.16
(0.00; 0.32)
−1.41 −1.29 −0.06
(−0.22; 0.10)
P = 0.06
Boys
Number 311 324 154 167 157 157
Median age in days 66 66 67 65 66 69
Weight, kg 4.38 4.42 0.00
(−0.09; 0.10)
4.39 4.33 0.08
(−0.05; 0.22)
4.37 4.52 −0.08
(−0.22; 0.06)
P = 0.15
Weight-for-age
(WAZ), z-score
−2.29 −2.23 0.01
(−0.15; 0.17)
−2.30 −2.34 0.06
(−0.15; 0.28)
−2.29 −2.11 −0.05
(−0.27; 0.17)
P = 0.54
Underweight
(WAZ < −2)
42% 40% 1.04
(0.88; 1.23)
44% 43% 1.02
(0.81; 1.28)
40% 38% 1.06
(0.83; 1.37)
P = 0.80
Length, cm 53.4 53.6 −0.04
(−0.41; 0.33)
53.3 53.3 0.10
(−0.42; 0.63)
53.5 53.9 −0.19
(−0.72; 0.34)
P = 0.47
Length-for-age
(LAZ), z-score
−2.91 −2.80 −0.01
(−0.17; 0.15)
−2.98 −2.89 −0.03
(−0.26; 0.19)
−2.85 −2.70 0.01
(−0.21; 0.24)
P = 0.75
Stunting (LAZ < −2) 61% 55% 1.08
(0.96; 1.21)
60% 60% 1.01
(0.86; 1.18)
62% 51% 1.15
(0.97; 1.37)
P = 0.69
Head circumference,
cm
37.8 37.8 0.10
(−0.13; 0.32)
38.0 37.6 0.37
(0.06; 0.69)
37.7 38.0 −0.19
(−0.51; 0.12)
P = 0.02
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Table 1 Neonatal vitamin A supplementation (VAS) and anthropometric measurements at 2 months, overall and by BCG-group (Continued)
Head circumference-
for-age, z-score
−1.46 −1.45 0.09
(−0.09; 0.26)
−1.37 −1.54 0.26
(0.01; 0.49)
−1.55 −1.35 −0.08
(−0.33; 0.16)
P = 0.06
Girls
Number 382 373 199 183 183 190
Median age in days 67 66 68 67 67 66
Weight, kg 4.14 4.18 −0.01
(−0.10; 0.08)
4.19 4.17 0.03
(−0.09; 0.16)
4.10 4.19 −0.06
(−0.19; 0.06)
P = 0.24
Weight-for-age
(WAZ), z-score
−2.00 −1.94 −0.04
(−0.18; 0.10)
−1.93 −2.01 0.07
(−0.13; 0.28)
−2.08 −1.87 −0.17
(−0.37; 0.04)
P = 0.08
Underweight
(WAZ < −2)
30% 33% 0.87
(0.72; 1.05)
28% 33% 0.82
(0.63; 1.07)
31% 34% 0.93
(0.72; 1.21)
P = 0.49
Length, cm 52.7 53.1 −0.18
(−0.52; 0.16)
52.7 53.2 −0.32
(−0.80; 0.16)
52.8 53.0 −0.03
(−0.52; 0.45)
P = 0.38
Length-for-age
(LAZ), z-score
−2.47 −2.30 −0.11
(−0.26; 0.03)
−2.51 −2.31 −0.15
(−0.36; 0.06)
−2.44 −2.30 −0.08
(−0.29; 0.13)
P = 0.63
Stunting (LAZ < −2) 44% 41% 1.03
(0.90; 1.18)
44% 40% 1.06
(0.88; 1.29)
43% 42% 1.00
(0.82; 1.21)
P = 0.80
Head circumference,
cm
37.1 37.1 0.03
(−0.17; 0.24)
37.2 37.1 0.06
(−0.23; 0.34)
37.0 37.0 0.00
(−0.29; 0.29)
P = 0.79
Head circumference-
for-age, z-score
−1.21 −1.24 0.02
(−0.14; 0.17)
−1.15 −1.24 0.07
(−0.15; 0.29)
−1.28 −1.24 −0.03
(−0.26; 0.19)
P = 0.51
*Analyses are adjusted for randomisation to BCG and weight/length/head circumference at inclusion.
**Analyses are adjusted for weight/length/head circumference at inclusion.
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effect if the child had received a DTP vaccine
(weight: -0.02 (−0.16; 0.10); head circumference: -0.08
(−0.23; 0.07)) (Table 2). Hence, there was a significant
interaction between VAS and DTP for head circum-
ference (interaction: p = 0.01) and a tendency towards
an interaction for weight (interaction p = 0.06). When
further stratifying on sex, the beneficial effect of VAS
on head circumference in the delayed DTP group was
most pronounced among girls (difference: 0.40 (0.12;
0.68)) whereas the beneficial effect on weight delayed
DTP group was most pronounced among boys (difference:
0.52 (0.24; 0.81)). This resulted in a statistically
significant 3-way interaction between sex, VAS, and
DTP for weight (interaction: p = 0.01). There was no
interaction between VAS and DTP for length at 6 months
after enrolment.
Stratified on weight group at inclusion, there was
no beneficial effect of VAS among the different
weight groups on weight-for-age, length-for-age and
head-circumference-for-age at 2 months (Table 3).
Among the smallest girls (weight < 1.5 kg) there was a
negative effect of VAS on weight-for-age and head
circumference-for-age.
Discussion
There was no effect of neonatal VAS on growth in the
first year of life among LBW children with a supposedly
low vitamin A status; in particular there was no beneficial
effect among the smallest children with a birth weight
below 1.5 kg, who if anything had a negative effect of VAS
on weight and head circumference. VAS tended to
have beneficial effect on weight and head circumference
at 2 months of age when given with BCG, but not when
given alone. VAS had a beneficial effect on head
circumference and weight at 6 months of age in children
who had received a late DTP vaccine, but not in childrenTable 2 Neonatal vitamin A supplementation (VAS) and anthrop
All
N VAS Placebo Difference*
(CI: 95%)
N VAS
Weight-for-age at 6 months, z-score
DTP at 2 months 715 −1.24 −1.23 −0.02 (−0.16; 0.10) 336 −1.39
No DTP at 2 months 380 −1.67 −1.71 0.18 (0.00; 0.36) 154 −1.64
Length-for-age at 6 months, z-score
DTP at 2 months 724 −1.69 −1.71 0.06 (−0.09; 0.22) 343 −1.95
No DTP at 2 months 387 −2.13 −2.02 0.03 (−0.19; 0.24) 160 −2.35
Head circumference-for-age at 6 months, z-score
DTP at 2 months 723 −0.60 −0.56 −0.08 (−0.24; 0.07) 340 −0.70
No DTP at 2 months 385 −0.61 −0.79 0.27 (0.06; 0.48) 160 −0.83
*All regression analyses are controlled for randomisation to BCG and weight/lengthwho had received the recommended DTP vaccine before
two months of age.
Consistency with previous studies
The lack of overall effect on infant growth of
neonatal VAS found in the present study is in line
with the results from previous studies on neonatal
VAS [6,7] as well as the results from supplementation later
in childhood [4]. A previous trial from Guinea-Bissau that
studied the effect on growth of neonatal VAS among
NBW infants found a tendency towards a negative
effect among girls when DTP was the most recent
vaccine [7]. These findings were partly supported by
the results from the present study where there was a
beneficial effect of VAS on weight and head circumference
at 6 months only among the children who had
received delayed DTP – though these effects were
seen for both sexes.
Strengths and weaknesses
The present study is the first to assess the effect of
neonatal VAS on growth among LBW infants with a
presumed poor vitamin A status. We used data from
a randomised trial where follow-up was based on
home visits. Only 12% were never measured and
these children showed the same distribution of back-
ground factors between the VAS and placebo groups.
It could be speculated that if mortality during follow-
up differed between the two groups, then a potential
effect of the intervention on growth could be masked,
but there was no strong difference in mortality
between the VAS and placebo groups. It has previ-
ously been shown in the present study population
that the delayed DTP group had significantly lower
anthropometric measurements indicating that the
healthiest children received DTP early [15]. Therefore,
we do not know if the tendency for a beneficial effectometric measurements at 6 months by 2 months DTP-status
Boys Girls
Placebo Difference*
(CI: 95%)
N VAS Placebo Difference*
(CI: 95%)
−1.31 −0.05 (−0.25; 0.14) 379 −1.11 −1.15 −0.01 (−0.19; 0.18)
−2.14 0.52 (0.24; 0.81) 226 −1.68 −1.39 −0.06 (−0.30; 0.18)
−1.83 −0.08 (−0.32; 0.14) 381 −1.45 −1.59 0.20 (−0.02; 0.41)
−2.30 0.08 (−0.25; 0.41) 227 −1.99 −1.81 −0.02 (−0.30; 0.26)
−0.59 −0.13 (−0.35: 0.10) 383 −0.52 −0.54 −0.04 (−0.25; 0.17)
−0.87 0.08 (−0.24; 0.41) 225 −0.47 −0.73 0.40 (0.12; 0.68)
/head circumference at 2 months.
Table 3 Neonatal vitamin A supplementation (VAS) and weight, length and head circumference at 2 months by weight
at inclusion
N VAS Placebo Difference*
(CI: 95%)
N VAS Placebo Difference*
(CI: 95%)
N VAS Placebo Difference*
(CI: 95%)
Weight-for-age, z-score
<1.5 kg 86 −4.82 −4.44 −0.31 (−0.73; 0.11) 32 −5.04 −5.07 0.12 (−0.56; 0.81) 54 −4.69 −4.09 −0.55 (−1.07; -0.02)
1.5-1.99 kg 360 −2.86 −2.88 −0.10 (−0.27; 0.14) 166 −3.12 −3.16 −0.08 (−0.38; 0.22) 194 −2.64 −2.64 −0.03 (−0.31; 0.24)
2.00-2.49 kg 939 −1.58 −1.58 0.02 (−0-10; 0.16) 434 −1.71 −1.72 0.05 (−0.13; 0.24) 505 −1.47 −1.44 0.00 (−0.17; 0.17)
Length for age at 2 months, z-score
<1.5 kg 86 −5.71 −5.23 −0.31 (−0.83; 0.21) 32 −5.98 −6.26 0.09 (−0.71; 0.90) 54 −5.54 −4.66 −0.51 (−1.18; 0.16)
1.5-1.99 kg 362 −3.34 −3.33 −0.03 (−0.28; 0.21) 168 −3.66 −3.76 0.09 (−0.23; 0.42) 194 −3.06 −2.97 −0.12 (−0.46; 0.23)
2.00-2.49 kg 940 −2.10 −2.01 −0.06 (−0.18; 0.06) 434 −2.34 −2.24 −0.05 (−0.24; 0.14) 506 −1.93 −1.80 −0.09 (−0.24; 0.06)
Head circumference for age at 2 months, z-score
<1.5 kg 86 −3.86 −3.25 −0.51 (−1.01; -0.01) 32 −4.29 −3.84 −0.18 (−1.02; 0.67) 54 −3.59 −2.92 −0.63 (−1.23; -0.02)
1.5-1.99 kg 362 −1.87 −1.98 0.08 (−0.13; 0.29) 168 −2.02 −2.19 0.13 (−0.19; 0.45) 194 −1.73 −1.82 0.05 (−0.23; 0.33)
2.00-2.49 kg 937 −0.86 −0.94 0.10 (−0.03; 0.22) 432 −0.98 −1.04 0.10 (−0.09; 0.30) 505 −0.76 −0.84 0.08 (−0.08; 0.25)
*All regression analyses are controlled for randomisation to BCG and weight/length/head circumference at inclusion.
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among the smallest children with the poorest vitamin
A status or an effect of VAS and delayed DTP, but it
should be noted that there was no general tendency
for a better effect in the smallest children. The vita-
min A status of the children included in the study
was not measured and we used birth weight as an
indicator for vitamin A status. Though it would have
been optimal to have individual vitamin A status
assessed, it has been shown consistently that birth
weight is a valid indicator of vitamin A status [8,9].
Interpretation
We found no indications that neonatal VAS has
strong effects on childhood growth. However, we
found a tendency towards a positive effect on weight
and head circumference when VAS was given with
BCG and a negative effect when given without BCG.
These results could support our previous hypotheses
that VAS amplifies the positive effects of BCG [11].
Furthermore, the timing of the DTP vaccination
might influence the effect of VAS on growth at
6 months suggesting that neonatal VAS might amplify
a negative effect of DTP or the negative effect of
DTP might hinder a beneficial effect of VAS given
with BCG. The biological mechanisms behind these
effects are unknown.
The beneficial effect of neonatal VAS given with
BCG was only seen 2 months after inclusion; 6 and
12 months after inclusion there was no effect of VAS.
These results could indicate that the children might
have had short term benefits from neonatal VAS
correcting a potential vitamin A deficiency at baseline.Later on during the child’s first year of life the vita-
min A deficiency might return. However, this would
not explain why an initial positive effect of neonatal
VAS at 2 months had disappeared at 6 and 12 months.
As argued previously it is more likely explained by a
negative interaction between VAS and DTP [21]. This
is supported by the present study which showed a
beneficial effect on weight and head circumference at
6 months after inclusion only among children who
had received DTP after 2 months suggesting that the
overall no effect at 6 months after inclusion might be
caused by the majority of the children receiving DTP
before 2 months.
Studies have shown consistently that smaller new-
borns have poorer vitamin A status [8,9]. However,
in our study cohort of LBW infants we found no
overall effect of VAS on growth suggesting that even
supposedly deficient newborns do not benefit from
neonatal VAS.
When we investigated the effect of VAS on mortal-
ity, no interaction between VAS and BCG was found,
but when looking at the effect on anthropometry we
found a tendency towards a different effect of VAS
when given with or without BCG. Growth might be
a more sensitive outcome than mortality enabling us
to discover more subtle differences in effects.
Conclusions
Overall there was no effect of providing 25,000 IU VAS
at birth on growth in the first year of life among LBW
children with a presumed low vitamin A status
suggesting that neonatal VAS does not impact growth
even within this population.
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